Results 151 to 160 of about 3,072,572 (310)

Safety Assessment

Journal of Japan Oil Chemists' Society, 1984
Toshiaki KOBAYASHI, Fujio MORIKAWA
openaire   +4 more sources

Ofatumumab in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease: A Comparison With Rituximab

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To evaluate the efficacy and safety of ofatumumab in patients with myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD), and compare it with rituximab. Methods We conducted a single–center, observational study including 22 MOGAD patients treated with ofatumumab and 21 treated with rituximab.
Yuxin Fan, Lei Zhou, Jingzi ZhangBao, Hongmei Tan, Zhouzhou Wang, Chao Quan   +5 more
wiley   +1 more source

Safety and Tolerability of Givinostat: Evidence From Real‐World and Clinical Practice

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The aim of our study was to establish the prevalence of adverse events in a real‐world setting in boys living with Duchenne muscular dystrophy (DMD) treated with givinostat as part of an Expanded Access Program (EAP) in Italy. Methods The cohort included 90 ambulant boys, with age when treatment started between 6 and 23 years (mean ...
Marika Pane, Anna Capasso, Chiara Arpaia, Adele D’Amico, Emilio Albamonte, Federica Trucco, Maria Sframeli, Riccardo Masson, Francesca Magri, Luca Bello, Romina Venditti, Claudia Dosi, Michela Catteruccia, Michele Tosi, Claudio Bruno, Sonia Messina, Giacomo Comi, Elena Pegoraro, Valeria A. Sansone, Eugenio Mercuri   +19 more
wiley   +1 more source

Assessment of the efficacy and safety of fampridine.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, 2017
Abstract Objective: Assessment of the efficacy and safety of fampridine for walking improvement in adult patients with multiple sclerosis. Method: A descriptive retrospective study of all patients who initiated treatment with fampridine between March, 2014 and February, 2015.
Mejuto, Beatriz, Castellano, Paloma, Castro, Concepción, López, Luis Manuel   +3 more
openaire   +4 more sources

Safety assessment of temporal interference stimulation. [PDF]

Front Neurosci
Hou R, Acerbo E, Yoshimoto R, Laxpati NG, Berglund K, Gutekunst CA.   +5 more
europepmc   +1 more source

Risk of Non‐Arteritic Anterior Ischemic Optic Neuropathy in Idiopathic Intracranial Hypertension Patients Treated with GLP‐1 Receptor Agonists

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have demonstrated significant weight‐reducing effects and may offer benefits in idiopathic intracranial hypertension (IIH); however, recent concerns about the risk of non‐arteritic anterior ischemic optic neuropathy (NAION) have emerged.
Faisal A. Al‐Harbi, Mohanad A. Alkuwaiti, Yazeed B. Alaql, Ahmed K. Alsaif, Ahmed A. Alessa, Meshari Ayed Alharbi, Mohammed Alfalah, Saud A. Alnaaim, Sajjad M. AlHaddad, Ahmed Y. Azzam   +9 more
wiley   +1 more source

THE MANAGEMENT OF OCCUPATIONAL HEALTH AND SAFETY IN ROMANIA [PDF]

The management of occupational health and safety constitutes the missing link as concerns the elaboration and implementation of integrated management systems i.e.
Marius Mitrache
core  

Movement Disorders in Aicardi–Goutières Syndrome and Response to Immunomodulation

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT This study characterizes movement disorders and treatment responses in seven children with Aicardi–Goutières syndrome (AGS). We retrospectively evaluated motor phenotypes, neuroimaging, and interferon signatures in patients treated with baricitinib or anifrolumab. Spasticity affected all patients, while dystonia was present in 4/7.
Enrique Gonzalez Saez‐Diez, Monica Ferrer Socorro, Kathryn Yang, Nicole Battaglia, Zainab Zaman, Mariko Bennett, Adeline Vanderver, Pui Y. Lee, Lauren A. Henderson, Milena M. Andzelm, Darius Ebrahimi‐Fakhari   +10 more
wiley   +1 more source

Safety assessment of poly(2-ethyl-2-oxazoline) for use in food contact materials. [PDF]

EFSA J
EFSA Panel on Food Contact Materials (FCM), Lambré C, Crebelli R, da Silva MJ, Grob K, Lampi E, Milana MR, Pronk M, Ščetar M, Theodoridis G, Van Hoeck E, Waegeneers N, Cariou R, Castle L, Di Consiglio E, Franz R, Barthélémy E, Comandella D, Rivière G.   +18 more
europepmc   +1 more source

Salmonellosis Control: Estimated Economic Benefits [PDF]

Salmonellosis, a common human intestinal disorder primarily caused by contaminated meats and poultry, attacks an estimated two million Americans annually. Using a cost of illness approach, the medical costs and productivity losses alone were estimated to
Roberts, Tanya
core   +1 more source